## Jocelyne Moisan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2419098/publications.pdf

Version: 2024-02-01

567281 642732 39 611 15 23 citations h-index g-index papers 39 39 39 872 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Adherence and sustained virologic response among vulnerable people initiating an hepatitis C treatment at a nurse-led clinic: A non-experimental prospective cohort study based on clinical records. International Journal of Nursing Studies Advances, 2021, 3, 100029.	2.1	2
2	Comparative educational outcomes of an active versus passive learning continuing professional development activity on self-management support for respiratory educators: A non-randomized controlled mixed-methods study. Nurse Education in Practice, 2021, 57, 103256.	2.6	2
3	COPD-Specific Self-Management Support Provided by Trained Educators in Everyday Practice is Associated with Improved Quality of Life, Health-Directed Behaviors, and Skill and Technique Acquisition: A Convergent Embedded Mixed-Methods Study. Patient, 2020, 13, 103-119.	2.7	7
4	Reprint of: Psychosocial factors associated with pharmacists' antidepressant drug treatment monitoring. Journal of the American Pharmacists Association: JAPhA, 2020, 60, S34-S43.	1.5	1
5	Psychosocial factors associated with pharmacists' antidepressant drug treatment monitoring. Journal of the American Pharmacists Association: JAPhA, 2020, 60, 548-558.	1.5	4
6	Response to letter to the editor related to the retraction of a trial included in a meta-analysis of interventions to enhance oral medication adherence titled "Effectiveness and content analysis of interventions to enhance oral antidiabetic drug adherence in adults with type 2 diabetes: Systematic review and meta-analysis― Value in Health, 2019, 22, 264-266.	0.3	0
7	Measuring adherence to oral antidiabetic multi-drug treatment: Comparative validity of prescription claims-based adherence measures against hospitalization. Research in Social and Administrative Pharmacy, 2019, 15, 738-743.	3.0	4
8	Neighbourhood Material and Social Deprivation and Exposure to Antidepressant Drug Treatment: A Cohort Study Using Administrative Data. Canadian Journal of Psychiatry, 2018, 63, 701-711.	1.9	4
9	Patient perspectives on the role of community pharmacists for antidepressant treatment: A qualitative study. Canadian Pharmacists Journal, 2018, 151, 142-148.	0.8	20
10	Factors associated with adherence to asthma treatment with inhaled corticosteroids: A cross-sectional exploratory study. Journal of Asthma, 2018, 55, 318-329.	1.7	17
11	Association between community pharmacy loyalty and persistence and implementation of antipsychotic treatment among individuals with schizophrenia. Research in Social and Administrative Pharmacy, 2018, 14, 53-61.	3.0	9
12	Comparative impact of two continuing education activities targeted at COPD educators on educational outcomes: protocol for a non-randomized controlled study using mixed methods. BMC Health Services Research, 2018, 18, 460.	2.2	3
13	The Development of a Community Pharmacy-Based Intervention to Optimize Patients' Use of and Experience with Antidepressants: A Step-by-Step Demonstration of the Intervention Mapping Process. Pharmacy (Basel, Switzerland), 2018, 6, 39.	1.6	7
14	Women's Beliefs on Early Adherence to Adjuvant Endocrine Therapy for Breast Cancer: A Theory-Based Qualitative Study to Guide the Development of Community Pharmacist Interventions. Pharmacy (Basel,) Tj ETQq	<sub>1</sub> 0 <b>0.</b> Ø rgBT	「∕ <b>O</b> werlock 10
15	Association between interpersonal continuity of care and medication adherence in type 2 diabetes: an observational cohort study. CMAJ Open, 2017, 5, E359-E364.	2.4	17
16	Factors associated with antidiabetic medication non-adherence in patients with incident comorbid depression. Journal of Diabetes and Its Complications, 2017, 31, 1200-1206.	2.3	16
17	Contributions of community pharmacists to patients on antidepressantsâ€"a qualitative study among key informants. International Journal of Clinical Pharmacy, 2017, 39, 686-696.	2.1	11
18	The Association between Depression and Medication Nonpersistence in New Users of Antidiabetic Drugs. Value in Health, 2017, 20, 728-735.	0.3	16

#	Article	IF	CITATIONS
19	Factors associated with β-blocker initiation and discontinuation in a population-based cohort of seniors newly diagnosed with heart failure. Patient Preference and Adherence, 2016, Volume 10, 1811-1821.	1.8	4
20	Persistence and compliance with newly initiated antihypertensive drug treatment in patients with chronic kidney disease. Patient Preference and Adherence, 2016, 10, 1121.	1.8	6
21	Revisiting the internal consistency and factorial validity of the 8-item Morisky Medication Adherence Scale. SAGE Open Medicine, 2016, 4, 205031211667485.	1.8	7
22	Psychosocial factors associated with adherence to non-insulin antidiabetes treatments. Journal of Diabetes and Its Complications, 2016, 30, 335-342.	2.3	25
23	Predictive Validity of Self-Reported Measures of Adherence to Noninsulin Antidiabetes Medication against Control of Glycated Hemoglobin Levels. Canadian Journal of Diabetes, 2016, 40, 58-65.	0.8	11
24	Patients' beliefs about adherence to oral antidiabetic treatment: a qualitative study. Patient Preference and Adherence, 2015, 9, 413.	1.8	27
25	Perspective of community pharmacists on their practice with patients who have an antidepressant drug treatment: Findings from a focus group study. Research in Social and Administrative Pharmacy, 2015, 11, e43-e56.	3.0	22
26	Effectiveness and Content Analysis of Interventions to Enhance Oral Antidiabetic Drug Adherence in Adults with Type 2 Diabetes: Systematic Review and Meta-Analysis. Value in Health, 2015, 18, 530-540.	0.3	28
27	Disentangling the influence of neighborhood and individual characteristics on early residential mobility among newly diagnosed patients with schizophrenia: a multilevel analysis. Social Psychiatry and Psychiatric Epidemiology, 2014, 49, 1569-1578.	3.1	6
28	Spatio-temporal clustering of the incidence of schizophrenia in Quebec, Canada from 2004 to 2007. Spatial and Spatio-temporal Epidemiology, 2013, 6, 37-47.	1.7	18
29	Does elapsed time between first diagnosis of schizophrenia and migration between health territories vary by place of residence? A survival analysis approach. Health and Place, 2013, 20, 66-74.	3.3	23
30	Hypoglycemia-Related Emergency Department Visits and Hypoglycemia-Related Hospitalizations among New Users of Antidiabetes Treatments. Canadian Journal of Diabetes, 2013, 37, 143-149.	0.8	13
31	Comparative Safety of Antipsychotics: Another Look at the Risk of Diabetes. Canadian Journal of Psychiatry, 2013, 58, 218-224.	1.9	10
32	Treatment prevalence and incidence of schizophrenia in Quebec using a population health services perspective: different algorithms, different estimates. Social Psychiatry and Psychiatric Epidemiology, 2012, 47, 533-543.	3.1	48
33	Patterns of discontinuation of atypical antipsychotics in the province of Qu $\tilde{A}$ ©bec: A retrospective prescription claims database analysis. Clinical Therapeutics, 2010, 32, S21-S31.	2.5	21
34	Ambulatory Use of Olanzapine and Risperidone: A Population-Based Study on Persistence and the Use of Concomitant Therapy in the Treatment of Schizophrenia. Canadian Journal of Psychiatry, 2005, 50, 901-908.	1.9	25
35	Exploring the risk of diabetes mellitus and dyslipidemia among ambulatory users of atypical antipsychotics: a population-based comparison of risperidone and olanzapine. Pharmacoepidemiology and Drug Safety, 2005, 14, 427-436.	1.9	20
36	A Pharmacy-Based Health Promotion Programme in Hypertension. Pharmacoeconomics, 2003, 21, 415-428.	3.3	30

#	Article	IF	CITATIONS
37	Non-Compliance with Drug Treatment and Reading Difficulties with Regard to Prescription Labelling among Seniors. Gerontology, 2002, 48, 44-51.	2.8	58
38	Billing for Cognitive Services: Understanding Qu $\tilde{A}$ ©bec Pharmacists' Behavior. Annals of Pharmacotherapy, 2000, 34, 309-316.	1.9	45
39	Preferred hydroxymethylglutaryl–coenzyme A reductase inhibitors: Treatment-modification program and outcomes. American Journal of Health-System Pharmacy, 1999, 56, 1437-1441.	1.0	6